热景生物
(688068)
| 流通市值：81.86亿 | | | 总市值：81.86亿 |
| 流通股本：9275.41万 | | | 总股本：9275.41万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 267,742,855.53 | 116,025,958 | 404,875,328.83 | 309,709,122.21 |
| 营业收入 | 267,742,855.53 | 116,025,958 | 404,875,328.83 | 309,709,122.21 |
| 二、营业总成本 | 425,798,962.15 | 205,096,020.9 | 658,410,281.34 | 421,420,697.99 |
| 营业成本 | 91,634,227.53 | 55,106,936.36 | 171,780,522.83 | 139,285,557.79 |
| 税金及附加 | 3,104,258.5 | 1,247,640.79 | 5,884,432.45 | 3,783,668.4 |
| 销售费用 | 166,419,670.83 | 71,531,419.33 | 220,578,633.29 | 151,132,777.93 |
| 管理费用 | 58,516,014.56 | 26,065,057.02 | 108,103,239.65 | 75,717,473.1 |
| 研发费用 | 95,129,164.66 | 49,095,971.2 | 162,283,848.15 | 67,477,321.52 |
| 财务费用 | 10,995,626.07 | 2,048,996.2 | -10,220,395.03 | -15,976,100.74 |
| 其中:利息费用 | 7,675,572.44 | 46,875 | 8,800,371.45 | 841,824.81 |
| 其中:利息收入 | 724,481.92 | 389,665.39 | 21,440,494.33 | 17,652,085.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -15,250,973.5 | -12,857,807.28 | -37,762,937.31 | -32,229,587.25 |
| 加:投资收益 | 18,651,532.67 | 15,050,621.23 | 60,668,645.45 | 28,465,336.44 |
| 资产处置收益 | -6,833.5 | -85.43 | 579,429.25 | 197,500.76 |
| 资产减值损失(新) | 29,301.65 | 204,404.43 | -43,432,490.1 | 161,560.18 |
| 信用减值损失(新) | -10,108,130.53 | 218,428.62 | -5,702,593.62 | -3,494,475.84 |
| 其他收益 | 6,116,103.37 | 4,212,617.84 | 14,287,380.98 | 6,910,202.22 |
| 四、营业利润 | -158,625,106.46 | -82,241,883.49 | -264,897,517.86 | -111,701,039.27 |
| 加:营业外收入 | 70,106.14 | 354,220.42 | 962,257.01 | 1,427,800.76 |
| 减:营业外支出 | 1,056,632.71 | 783,732.67 | 3,340,479.13 | 1,865,805.59 |
| 五、利润总额 | -159,611,633.03 | -82,671,395.74 | -267,275,739.98 | -112,139,044.1 |
| 减:所得税费用 | -802,120.47 | -5,777.7 | -8,640,820.68 | -1,657,432.61 |
| 六、净利润 | -158,809,512.56 | -82,665,618.04 | -258,634,919.3 | -110,481,611.5 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -158,809,512.56 | -82,665,618.04 | -258,634,919.3 | -110,481,611.5 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -126,127,467.18 | -68,059,381.05 | -216,045,116.97 | -108,959,463.59 |
| 少数股东损益 | -32,682,045.38 | -14,606,236.99 | -42,589,802.33 | -1,522,147.91 |
| 扣除非经常损益后的净利润 | -144,091,853.59 | -76,340,696.52 | -247,987,035.09 | -148,262,814.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.36 | -0.77 | -2.5 | -1.23 |
| (二)稀释每股收益 | -1.36 | -0.75 | -2.5 | -1.23 |
| 八、其他综合收益 | 29,799,414.12 | 2,708,234.04 | 13,420,525.92 | 5,114,949.56 |
| 归属于母公司股东的其他综合收益 | 29,785,122.72 | 2,708,234.04 | 13,405,324.3 | 5,102,943.23 |
| 九、综合收益总额 | -129,010,098.44 | -79,957,384 | -245,214,393.38 | -105,366,661.94 |
| 归属于母公司股东的综合收益总额 | -96,342,344.46 | -65,351,147.01 | -202,639,792.67 | -103,856,520.36 |
| 归属于少数股东的综合收益总额 | -32,667,753.98 | -14,606,236.99 | -42,574,600.71 | -1,510,141.58 |
| 公告日期 | 2026-08-27 | 2026-04-25 | 2026-04-25 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |